Danaher Corporation $DHR Stock Holdings Lifted by CI Investments Inc.

CI Investments Inc. lifted its holdings in shares of Danaher Corporation (NYSE:DHR) by 2.3% in the first quarter, Holdings Channel.com reports. The institutional investor owned 1,181,493 shares of the conglomerate’s stock after purchasing an additional 26,367 shares during the quarter. Danaher makes up 1.1% of CI Investments Inc.’s portfolio, making the stock its 15th largest holding. CI Investments Inc.’s holdings in Danaher were worth $224,011,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Enterprise Financial Services Corp lifted its holdings in shares of Danaher by 1.4% in the 4th quarter. Enterprise Financial Services Corp now owns 3,219 shares of the conglomerate’s stock worth $737,000 after purchasing an additional 46 shares during the last quarter. Kennebec Savings Bank lifted its stake in Danaher by 1.4% in the fourth quarter. Kennebec Savings Bank now owns 3,348 shares of the conglomerate’s stock valued at $766,000 after buying an additional 46 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Danaher by 2.6% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,870 shares of the conglomerate’s stock valued at $428,000 after acquiring an additional 47 shares during the period. High Note Wealth LLC boosted its holdings in shares of Danaher by 19.2% during the fourth quarter. High Note Wealth LLC now owns 292 shares of the conglomerate’s stock valued at $67,000 after acquiring an additional 47 shares during the period. Finally, First Command Advisory Services Inc. grew its position in shares of Danaher by 4.4% during the fourth quarter. First Command Advisory Services Inc. now owns 1,104 shares of the conglomerate’s stock worth $253,000 after acquiring an additional 47 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

Shares of Danaher stock opened at $179.01 on Wednesday. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The stock has a market cap of $126.70 billion, a PE ratio of 34.62, a price-to-earnings-growth ratio of 2.48 and a beta of 0.79. The company’s 50-day moving average price is $184.22 and its two-hundred day moving average price is $197.69. The company has a current ratio of 1.87, a quick ratio of 1.52 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.84 by $0.10. The firm had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.11 billion. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period last year, the firm posted $0.77 earnings per share. As a group, sell-side analysts anticipate that Danaher Corporation will post 8.45 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be given a $0.40 dividend. The ex-dividend date is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.9%. Danaher’s dividend payout ratio (DPR) is 30.95%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Wall Street Zen lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. JPMorgan Chase & Co. dropped their price target on shares of Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 22nd. Robert W. Baird cut their price target on Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Morgan Stanley reduced their price objective on Danaher from $270.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, April 22nd. Finally, HSBC lowered their target price on Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average price target of $231.64.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher posted Q2 adjusted EPS of $1.94, above the $1.84 consensus, and revenue of about $6.26 billion to $6.3 billion, also ahead of estimates. Danaher Reports Second Quarter 2026 Results
• Positive Sentiment: Management raised full-year adjusted EPS guidance, showing confidence in profitability despite the softer sales backdrop. Danaher Corp (DHR) Q2 2026 Earnings Call Highlights
• Neutral Sentiment: Life Sciences was a bright spot, with stronger sales growth, but bioprocessing revenue came in weaker than expected and was cited as a drag on sentiment. Reuters: Danaher’s revenue outlook cut, biotech miss overshadow profit forecast raise
• Negative Sentiment: Investors reacted negatively to the reduced core revenue growth outlook and cautious near-term guidance, which outweighed the earnings beat and led to the stock decline. Danaher stock slips despite Q2 earnings beat, raised guidance
• Negative Sentiment: Analysts also highlighted “surprisingly soft” bioprocessing sales, reinforcing concerns that growth may slow more than expected. Danaher Plummets After One Segment Comes In ‘Surprisingly Soft’

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.